Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
BMJ
; 374(n2015)2021.
Artículo
en Inglés
| Sec. Est. Saúde SP, SESSP-CTDPROD, Sec. Est. Saúde SP
| ID: biblio-1428647
Biblioteca responsable:
BR91.2
Ubicación: BR91.2; P
RESUMO
Objective To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo state, Brazil during widespread circulation of the gamma variant. Design Test negative case-control study. Setting Community testing for covid-19 in São Paulo state, Brazil. Participants 43 774 adults aged ≥70 years who were residents of São Paulo state and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 29 April 2021. 26 433 cases with symptomatic covid-19 and 17 622 test negative controls with covid-19 symptoms were formed into 13 283 matched sets, one case with to up to five controls, according to age, sex, self-reported race, municipality of residence, previous covid-19 status, and date of RT-PCR test (±3 days). Intervention Vaccination with a two dose regimen of CoronaVac. Main outcome measures RT-PCR confirmed symptomatic covid-19 and associated hospital admissions and deaths. Results Adjusted vaccine effectiveness against symptomatic covid-19 was 24.7% (95% confidence interval 14.7% to 33.4%) at 0-13 days and 46.8% (38.7% to 53.8%) at ≥14 days after the second dose. Adjusted vaccine effectiveness against hospital admissions was 55.5% (46.5% to 62.9%) and against deaths was 61.2% (48.9% to 70.5%) at ≥14 days after the second dose. Vaccine effectiveness ≥14 days after the second dose was highest for the youngest age group (70-74 years)59.0% (43.7% to 70.2%) against symptomatic disease, 77.6% (62.5% to 86.7%) against hospital admissions, and 83.9% (59.2% to 93.7%) against deathsand declined with increasing age. Conclusions Vaccination with CoronaVac was associated with a reduction in symptomatic covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive transmission of the gamma variant. Vaccine protection was, however, low until completion of the two dose regimen, and vaccine effectiveness was observe to decline with increasing age among this elderly population.
Texto completo:
Disponible
Colección:
Bases de datos nacionales
/
Brasil
Contexto en salud:
ODS3 - Meta 3.3 Poner fin a las enfermedades desatendidas y detener enfermedades transmisibles
Problema de salud:
COVID-19
Base de datos:
Sec. Est. Saúde SP
/
SESSP-CTDPROD
Asunto principal:
Efectividad
/
Vacunas
/
Epidemias
Tipo de estudio:
Estudio observacional
/
Factores de riesgo
País/Región como asunto:
America del Sur
/
Brasil
Idioma:
Inglés
Revista:
BMJ
Año:
2021
Tipo del documento:
Artículo
Institución/País de afiliación:
4Division of Infectious Diseases and Geographic Medicine/BR
/
Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain/BR
/
Department of Biology, University of Florida, Gainesville, FL, USA/BR
/
Department of Biostatistics, College of Public Health & Health Professions/BR
/
Department of Epidemiology of Microbial Diseases/BR
/
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA/BR
/
Disease Control Coordination of the São Paulo State/BR
/
Health Secretariat of the State of São Paulo, São Paulo, Brazil/BR
/
Municipal Health Secretary of Manaus, Brazil, AM, Brazil/BR
/
Pan American Health Organization, Brasília, DF, Brazil/BR